Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors

被引：16

作者：

El-Sharkawy, Lina Y. ^{[1
]}

El-Sakhawy, Rowaida A. ^{[1
]}

Abdel-Halim, Mohammad ^{[1
]}

Lee, Kevin ^{[2
]}

Piazza, Gary A. ^{[2
]}

Ducho, Christian ^{[3
]}

Hartmann, Rolf W. ^{[4
]}

Abadi, Ashraf H. ^{[1
]}

机构：

[1] German Univ Cairo, Fac Pharm & Biotechnol, Dept Pharmaceut Chem, Cairo 11835, Egypt

[2] Univ S Alabama, Drug Discovery Res Ctr, Mitchell Canc Inst, Mobile, AL USA

[3] Saarland Univ, Dept Pharm Pharmaceut & Med Chem, Saarbrucken, Germany

[4] Helmholtz Inst Pharmaceut Res Saarland HIPS, Dept Drug Design & Optimizat, Saarbrucken, Germany

来源：

ARCHIV DER PHARMAZIE | 2018年 / 351卷 / 05期

关键词：

annulated thienopyrimidines; cycloalkene-fused thienopyrimidines; phosphodiesterase inhibitor; planarity; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; DRUG DEVELOPMENT; DERIVATIVES; DISCOVERY; AGENTS;

D O I：

10.1002/ardp.201800018

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Novel cycloalkene-fused thienopyrimidine analogues with enhanced phosphodiesterase 5 (PDE5) inhibitory properties are presented. The structure of the reported scaffold was modulated through variation of the terminal cycloalkene ring size, as well as by varying the substituents at position 4 through the attachment of different groups including aniline, benzylamine, cyclohexylethylamine, methyl/acetyl/aryl piperazines, and aryl hydrazones. Compound 15Y with a benzylamine substituent and cycloheptene as terminal ring showed the highest PDE5 inhibitory activity with an IC50 value as low as 190 nM and with good selectivity versus PDE7 and PDE9.

引用

页数：17

共 50 条

[21] Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy [J].

Ibrahim, Tarek S. ;

Hawwas, Mohamed M. ;

Taher, Ehab S. ;

Alhakamy, Nabil A. ;

Alfaleh, Mohamed A. ;

Elagawany, Mohamed ;

Elgendy, Bahaa ;

Zayed, Gamal M. ;

Mohamed, Mamdouh F. A. ;

Abdel-Samii, Zakaria K. ;

Elshaier, Yaseen A. M. M. .

BIOORGANIC CHEMISTRY, 2020, 105

[22] From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity [J].

Abdel-Halim, Mohammad ;

Sigler, Sara ;

Racheed, Nora A. S. ;

Hefnawy, Amr ;

Fathalla, Reem K. ;

Hammam, Mennatallah A. ;

Maher, Ahmed ;

Maxuitenko, Yulia ;

Keeton, Adam B. ;

Hartmann, Rolf W. ;

Engel, Matthias ;

Piazza, Gary A. ;

Abadi, Ashraf H. .

JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (08) :4462-4477

[23] Targeting cyclic nucleotide phosphodiesterase 5 (PDE5) in brain: Toward the development of a PET radioligand labeled with fluorine-18 [J].

Wenzel, Barbara ;

Liu, Jianrong ;

Dukic-Stefanovic, Sladjana ;

Deuther-Conrad, Winnie ;

Teodoro, Rodrigo ;

Ludwig, Friedrich-Alexander ;

Chezal, Jean-Michel ;

Moreau, Emmanuel ;

Brust, Peter ;

Maisonial-Besset, Aurelie .

BIOORGANIC CHEMISTRY, 2019, 86 :346-362

[24] Design of Novel β-Carboline Derivatives with Pendant 5-Bromothienyl and Their Evaluation as Phosphodiesterase-5 Inhibitors [J].

El-Gamil, Dalia S. ;

Ahmed, Nermin S. ;

Gary, Bernard D. ;

Piazza, Gary A. ;

Engel, Matthias ;

Hartmann, Rolf W. ;

Abadi, Ashraf H. .

ARCHIV DER PHARMAZIE, 2013, 346 (01) :23-33

[25] Advances in the development of phosphodiesterase 5 inhibitors [J].

Zong, Tieqiang ;

Huang, Xing ;

Zhou, Wei ;

Hu, Zhengyu ;

Jin, Long ;

Zhan, Peng ;

Zhao, Yuqing ;

Sun, Jinfeng ;

Li, Gao .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 287

[26] Pharmacophore based virtual screening, molecular docking and biological evaluation to identify novel PDE5 inhibitors with vasodilatory activity [J].

Mittal, Anupama ;

Paliwal, Sarvesh ;

Sharma, Mukta ;

Singh, Aarti ;

Sharma, Swapnil ;

Yadav, Divya .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (14) :3137-3141

[27] Is There a Role for PDE5 Inhibitors in the Management of Male Infertility Due to Defects in Testicular or Epididymal Function? [J].

Dimitriadis, F. ;

Tsounapi, P. ;

Saito, M. ;

Watanabe, T. ;

Sylakos, A. ;

Tsabalas, S. ;

Miyagawa, I. ;

Sofikitis, N. .

CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (30) :3506-3520

[28] In Silico Mapping of Essential Residues in the Catalytic Domain of PDE5 Responsible for Stabilization of Its Commercial Inhibitors [J].

de Oliveira, Ivan Pires ;

Lescano, Caroline Honaiser ;

De Nucci, Gilberto .

SCIENTIA PHARMACEUTICA, 2019, 87 (04)

[29] Synthesis, docking studies and in vitro evaluation of novel chalcones as potent inhibitors of phosphodiesterase 5 from human platelets and 5A from bovine recombinant [J].

Sherikar, Amol S. ;

Dhavale, Rakesh P. ;

Bhatia, Manish S. .

NEW JOURNAL OF CHEMISTRY, 2018, 42 (17) :14365-14385

[30] In silico screening of anthraquinones from Prismatomeris memecyloides as novel phosphodiesterase type-5 inhibitors (PDE-51s) [J].

Pham Ngoc Khanh ;

Tran Thu Huong ;

Spiga, Ottavia ;

Trezza, Alfonso ;

Ninh The Son ;

To Dao Cuong ;

Vu Thi Ha ;

Nguyen Manh Cuong .

REVISTA INTERNACIONAL DE ANDROLOGIA, 2018, 16 (04) :147-158

← 1 2 3 4 5 →